, Volume 69, Issue 6, pp 739–756 | Cite as

Ferric Carboxymaltose

A Review of its Use in Iron-Deficiency Anaemia
  • Katherine A. Lyseng-Williamson
  • Gillian M. Keating
Adis Drug Evaluation



Ferric carboxymaltose (Ferinject®), a novel iron complex that consists of a ferric hydroxide core stabilized by a carbohydrate shell, allows for controlled delivery of iron to target tissues. Administered intravenously, it is effective in the treatment of iron-deficiency anaemia, delivering a replenishment dose of up to 1000 mg of iron during a minimum administration time of ≤15 minutes. Results of several randomized trials have shown that intravenously administered ferric carboxymaltose rapidly improves haemoglobin levels and replenishes depleted iron stores in various populations of patients with iron-deficiency anaemia, including those with inflammatory bowel disease, heavy uterine bleeding, postpartum irondeficiency anaemia or chronic kidney disease. It was well tolerated in clinical trials. Ferric carboxymaltose is, therefore, an effective option in the treatment of iron-deficiency anaemia in patients for whom oral iron preparations are ineffective or cannot be administered.

Pharmacological Properties

Ferric carboxymaltose is a macromolecular ferric hydroxide carbohydrate complex, which allows for controlled delivery of iron within the cells of the reticuloendothelial system and subsequent delivery to the iron-binding proteins ferritin and transferrin, with minimal risk of release of large amounts of ionic iron in the serum. Intravenous administration of ferric carboxymaltose results in transient elevations in serum iron, serum ferritin and transferrin saturation, and, ultimately, in the correction of haemoglobin levels and replenishment of depleted iron stores.

The total iron concentration in the serum increased rapidly in a dose-dependent manner after intravenous administration of ferric carboxymaltose. Ferric carboxymaltose is rapidly cleared from the circulation and is distributed primarily to the bone marrow (≈80%) and also to the liver and spleen. Repeated weekly administration of ferric carboxymaltose does not result in accumulation of transferrin iron in patients with iron-deficiency anaemia.

Therapeutic Efficacy

Intravenously administered ferric carboxymaltose was effective in the treatment of iron-deficiency anaemia in several 6- to 12-week, randomized, open-label, controlled, multicentre trials in various patient populations, including those with inflammatory bowel disease, heavy uterine bleeding or postpartum irondeficiency anaemia, and those with chronic kidney disease not undergoing or undergoing haemodialysis. In most trials, patients received either ferric carboxymaltose equivalent to an iron dose of ≤1000mg (or 15mg/kg in those weighing <66kg) administered over ≤15 minutes (subsequent doses administered at 1-week intervals) or oral ferrous sulfate at a dose equivalent to 65 mg iron three times daily or 100mg iron twice daily. In one trial, patients with chronic kidney disease undergoing haemodialysis received 200 mg of iron intravenously either as ferric carboxymaltose or iron sucrose administered into the haemodialysis line two to three times weekly. In all trials, ferric carboxymaltose was administered until each patient had received his or her calculated total iron replacement dose.

Haemoglobin-related outcomes improved in patients with iron-deficiency anaemia receiving ferric carboxymaltose. Treatment with ferric carboxymaltose was associated with rapid and sustained increases from baseline in haemoglobin levels. Ferric carboxymaltose was considered to be as least as effective as ferrous sulfate with regard to changes from baseline in haemoglobin levels or the proportion of patients achieving a haematopoietic response at various timepoints. In general, improvements in haemoglobin levels were more rapid with ferric carboxymaltose than with ferrous sulfate. In patients with chronic kidney disease undergoing haemodialysis, ferric carboxymaltose was at least as effective as iron sucrose.

Ferric carboxymaltose also replenished depleted iron stores and improved health-related quality-of-life (HR-QOL) in patients with iron-deficiency anaemia. Recipients of ferric carboxymaltose demonstrated improvements from baseline in serum ferritin levels and transferrin saturation, as well as improvements from baseline in HR-QOL assessment scores. Ferric carboxymaltose was at least as effective as ferrous sulfate with regard to endpoints related to serum ferritin levels, transferrin saturation and HR-QOL.


Ferric carboxymaltose was well tolerated in clinical trials in patients with irondeficiency anaemia, with most drug-related adverse events considered to be mild to moderate in severity. Commonly reported drug-related adverse events include headache, dizziness, nausea, abdominal pain, constipation, diarrhoea, rash and injection-site reactions.

The incidence of drug-related adverse events in patients receiving intravenous ferric carboxymaltose was generally similar to that in patients receiving oral ferrous sulfate. In general, rash and local injection-site reactions were more common with ferric carboxymaltose, whereas gastrointestinal adverse events were more frequent with ferrous sulfate. In patients with chronic kidney disease undergoing haemodialysis, a lower proportion of ferric carboxymaltose than iron sucrose recipients experienced at least one drug-related adverse event.


  1. 1.
    World Health Organization. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. Geneva: World Health Organization, 2001Google Scholar
  2. 2.
    de Benoist B, McLean E, Egli I, et al. Worldwide prevalence of anaemia 1993–2005: WHO Global Database. Geneva: World Health Organization, 2008Google Scholar
  3. 3.
    Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008; 13(4): 393–404PubMedCrossRefGoogle Scholar
  4. 4.
    Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol 2007; 13(36): 4798–806PubMedGoogle Scholar
  5. 5.
    Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther 2006 Dec; 24(11–12): 1507–23PubMedCrossRefGoogle Scholar
  6. 6.
    Dodd J, Dare M, Middleton P. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database Syst Rev 2004; (4): CD004222Google Scholar
  7. 7.
    Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008 May; 103(5): 1299–307PubMedCrossRefGoogle Scholar
  8. 8.
    Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol 2009; 25(2): 122–8PubMedCrossRefGoogle Scholar
  9. 9.
    Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13(12): 1545–53PubMedCrossRefGoogle Scholar
  10. 10.
    National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults: using iron agents [online]. Available from URL: http://www.kidney.org/professionals/kdoqi/guidelines_anemia/cpr32.htm [Accessed 2009 Jan 22]
  11. 11.
    Madore F, White CT, Foley RN, et al. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int 2008 Aug; 74 Suppl. 110: S7–11CrossRefGoogle Scholar
  12. 12.
    National Institute for Health and Clinical Excellence. Anaemia management in people with chronic kidney disease. NICE clinical guideline 39. London: National Institute for Health and Clinical Excellence, 2006 SepGoogle Scholar
  13. 13.
    Locatelli F, Pisoni RL, Combe C. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dialysis Transplant 2004; 19(1): 121–32CrossRefGoogle Scholar
  14. 14.
    Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008 Nov; 52(5): 897–906PubMedCrossRefGoogle Scholar
  15. 15.
    Locatelli F, Aljama P, Bárány P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Section III: treatment of renal anaemia. Nephrol Dial Transplant 2004 May; 19 Suppl. 2: ii16–31CrossRefGoogle Scholar
  16. 16.
    UK Medicines and Healthcare Products Regulatory Agency. Public assessment report (decentralised procedure): Ferinject 50mg iron/ml solution for injection/infusion (PL 15240/0002; UK/H/0894/001/DC) [online]. Available from URL: http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con014025.pdf [Accessed 2008 Dec 9]
  17. 17.
    Ferinject: UK summary of product characteristics. Purley: Syner-Med (Pharmaceutical Products) Ltd, 2007 Jul 17Google Scholar
  18. 18.
    Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009; 23(1): 11–6Google Scholar
  19. 19.
    Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992; 42(12): 1439–52PubMedGoogle Scholar
  20. 20.
    Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004 Dec; 15 Suppl. 2: S93–8PubMedGoogle Scholar
  21. 21.
    Beshara S, Sörensen J, Lubberink M, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003 Mar; 120(5): 853–9PubMedCrossRefGoogle Scholar
  22. 22.
    Geisser P, Banké-Bochita J. The pharmacokinetics, safety and tolerability of ferric carboxymaltose: data from a dose escalating study in patients with iron deficiency anaemia [abstract no. MP382 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
  23. 23.
    Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (Ferinject®) randomized controlled trial. Am J Gastroenterol 2008 May; 103(5): 1182–92PubMedCrossRefGoogle Scholar
  24. 24.
    Gordon SS, Hadley PE, Van Wyck DB, et al. Iron carboxymaltose, a new intravenous iron agent for iron deficiency anemia in heavy uterine bleeding [abstract]. Obstet Gynecol 2007 Apr; 109 (4 Suppl.): 108SGoogle Scholar
  25. 25.
    Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008 Apr; 101(1): 67–73PubMedCrossRefGoogle Scholar
  26. 26.
    Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008 Oct; 199(4): 435.e1-7PubMedCrossRefGoogle Scholar
  27. 27.
    Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007 Aug; 110 (2 Pt 1): 267–78PubMedCrossRefGoogle Scholar
  28. 28.
    Qunibi WY, Martinez C, Smith M, et al. Efficacy and safety of IV ferric carboxymaltose (FCM) compared to oral iron in anemic patients with non-dialysis-dependent CKD [abstract no. MO017 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
  29. 29.
    Schaefer RM, Khasabov NN, Todorov NG, et al. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia [abstract no. MP375 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
  30. 30.
    Agarwal R. Iron, oxidative stress, and clinical outcomes. Pediatr Nephrol 2008; 23(8): 1195–9PubMedCrossRefGoogle Scholar
  31. 31.
    Toblli JE, Cao G, Oliveri L, et al. Evaluation of intravenous iron preparations on cardiovascular toxicity in normal rats [abstract no. PUB476]. American Society of Nephrology Renal Week; 2008 Nov 4–9; Philadelphia (PA)Google Scholar
  32. 32.
    Manley HJ, McClaran ML. Determination of VIT 45 (IND#63,243 American Regent) removal by closed loop in vitro hemodialysis system. Int J Artif Organs 2006 Nov; 29(11): 1062–6PubMedGoogle Scholar
  33. 33.
    Seid MH, Mangione A, Valaoras TG, et al. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia [abstract no. 3739]. Blood 2006 Nov 2; 108 (11 Pt 2): 8bGoogle Scholar
  34. 34.
    Qunibi W, Dinh Q, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM): data from the FCM clinical program [abstract no. MP383 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10–13; StockholmGoogle Scholar
  35. 35.
    Vifor Pharma. Overview of the safety of Ferinject (ferric carboxymaltose, FCM) in the clinical trial programme. St Gallen, Switzerland; Vifor (International), Inc., 2009 Jan 19 (Data on file)Google Scholar
  36. 36.
    Lu M. Injectafer® (iron carboxymaltose injection):NDA 22054: slide presentation [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4337s1-05-FDA-Lu.ppt [Accessed 2008 Dec 11]
  37. 37.
    Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Drug Safety and Risk Management Advisory Committee, February 1, 2008 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4337m1-Final.pdf [Accessed 2008 Dec 11]
  38. 38.
    US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 16]
  39. 39.
    Tagboto S, Cropper L, Turner J, et al. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject®) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Ren Care 2009 Mar; 35(1): 18–23PubMedCrossRefGoogle Scholar
  40. 40.
    Grimmelt A-C, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009 Feb; 71(2): 125–9Google Scholar
  41. 41.
    European Medicines Agency. CosmoFer: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=14139 [Accessed 2009 Jan 21]
  42. 42.
    European Medicines Agency. Venofer 20 mg/ml solution for injection: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=14438 [Accessed 2009 Jan 21]
  43. 43.
    Ferrlecit® (sodium ferric gluconate complex in sucrose injection): US product monograph. Corona (CA): Watson Pharma, Inc., 2003 Apr 13Google Scholar
  44. 44.
    Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006 Feb; 21(2): 378–82PubMedCrossRefGoogle Scholar
  45. 45.
    Sengölge G, Hörl W, Sunder-Plassmann G. Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 2005 Dec; 35 Suppl. 3: 46–51PubMedCrossRefGoogle Scholar
  46. 46.
    Steiner S, Brock E, Schneider H, et al. Budget impact (BI) of parenteral iron treatment of iron deficiency anaemia (IDA) in Switzerland [abstract no. PHM2]. Value Health 2007 Nov; 10(6): A280CrossRefGoogle Scholar
  47. 47.
    Littlewood TJ, Alikhan R. The use of intravenous iron in patients with cancer-related anaemia. Br J Haematol 2008; 141(6): 751–6PubMedCrossRefGoogle Scholar
  48. 48.
    Ludwig H. Iron metabolism and iron supplementation in anemia of cancer. Semin Hematol 2006 Oct; 43 (4 Suppl. 6): S13–7CrossRefGoogle Scholar
  49. 49.
    Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008 Aug 12; 52(7): 501–11PubMedCrossRefGoogle Scholar
  50. 50.
    Cavill I, Auerbach M, Bailie G, et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 2006 Apr; 22(4): 731–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Katherine A. Lyseng-Williamson
    • 1
    • 2
  • Gillian M. Keating
    • 1
    • 2
  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthPhiladelphiaUSA

Personalised recommendations